Open AccessDevelopment of Inhalable Nanostructured Lipid Carriers for Ciprofloxacin for Noncystic Fibrosis Bronchiectasis Treatment
Author(s) -
Alanood S. Almurshedi,
Hessah A Aljunaidel,
Bushra T. AlQuadeib,
Basmah N. Aldosari,
Iman M. Alfagih,
Salma S Almarshidy,
Eram Eltahir,
Amany Z Mohamoud
Publication year - 2021
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s286896
Subject(s) - materials science , particle size , ciprofloxacin hydrochloride , dry powder inhaler , stearic acid , aerosolization , aerodynamic diameter , drug carrier , dispersity , spray drying , chromatography , ciprofloxacin , inhalation , drug delivery , chemistry , aerosol , nanotechnology , inhaler , medicine , organic chemistry , biochemistry , composite material , antibiotics , asthma , polymer chemistry , anatomy
Ciprofloxacin (CIP) has poor lung targeting after oral inhalation. This study developed optimized inhalable nanostructured lipid carriers (NLCs) for CIP to enhance deposition and accumulation in deeper parts of the lungs for treatment of noncystic fibrosis bronchiectasis (NCFB).